Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor

Gynecologic and Obstetric Investigation

Volumn 72, Issue 4, 2011, Pages 269-273

  Arikan, I ^a,b   Barut, A ^a   Harma, M ^a   Harma, I M ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^b ZKÜ Týp Fakültesi Kadýn Hastalýklarý Ve Doum AD   (Turkey)

Author keywords

Micronized natural progesterone; Perinatal outcome; Preterm birth; Randomized trial

Indexed keywords

MICRONIZED NATURAL PROGESTERONE; PROGESTERONE; RITODRINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BIRTH WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LATENT PERIOD; LENGTH OF STAY; MAINTENANCE THERAPY; NEWBORN INTENSIVE CARE; NEWBORN SEPSIS; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; TOCOLYSIS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVAGINAL; BIRTH WEIGHT; CAPSULES; DRUG THERAPY, COMBINATION; FEMALE; GESTATIONAL AGE; HUMANS; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PROGESTERONE; PROGESTINS; RITODRINE; TOCOLYTIC AGENTS; TREATMENT OUTCOME;

EID: 83555162516     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000328719     Document Type: Article

References (21)

1. World Health Organization: Recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO October 14, 1976. Acta Obstet Gynecol Scand 1977; 56: 247-253.
2. Tita AT, Rouse DJ: Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol 2009; 200: 219-224.
3. Borna S, Sahabi N: Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2008; 48: 58-63. (Pubitemid 351239131)
4. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A: Cervical length changes during preterm cervical ripening: effects of 17α- hydroxyprogesterone caproate. Am J Obstet Gynecol 2007; 196: 453-454.
5. Thornton JG: Maintenance tocolysis. BJOG 2005; 112(suppl 1):118-121. (Pubitemid 40313996)
6. Dodd JM, Crowther CA, Dare MR, Middleton P: Oral β-mimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst Rev 2006;CD003927.
7. Papatsonis D, Flenady V, Liley H: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2009;CD005938.
8. Papiernik-Berkhauer E: Double-blind study of an agent to prevent preterm delivery among women at increased risk. Edition Schering, series IV, 1970, pp 65-68.
9. Kauppila A, Hartikainen-Sorri AL, Jänne O, Tuimala R, Järvinen PA: Suppression of threatened premature labor by administration of cortisol and 17α-hydroxyprogesterone caproate: a comparison with ritodrine. Am J Obstet Gynecol 1980; 138: 404-408. (Pubitemid 11226070)
10. Erny R, Pigne A, Prouvost C, Gamerre M, Malet C, Serment H, Barrat J: The potential tocolytic effect of natural progesterone administration on premature. Am J Obstet Gynecol 1986; 154: 525-529. (Pubitemid 16128013)
11. Noblot G, Audra P, Dargent D, Faguer B, Mellier G: The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol 1991; 40: 203-209.
12. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH: Progesterone and the risk of preterm birth among women with a short cervix. Fetal Medicine Foundation Second Trimester Screening Group. N Engl J Med 2007; 357: 462-469. (Pubitemid 47204875)
13. DeFranco EA, O'Brien JM, Adair CD, et al: Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 697-705. (Pubitemid 47612690)
14. Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M: Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419-424. (Pubitemid 36249980)
15. Meis PJ, Klebanoff M, Thom E, et al: Prevention of recurrent preterm delivery by 17α-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385. (Pubitemid 36682816)
16. Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A, Das A, et al: The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med 1996; 334: 567-572. (Pubitemid 26066130)
17. To MS, Skentou CA, Royston P, Yu CK, Nicolaides KH, et al: Prediction of patient-specific risk of early preterm delivery using maternal history and sonographic measurement of cervical length: a population-based prospective study. Ultrasound Obstet Gynecol 2006; 27: 362-367. (Pubitemid 43735473)
18. Grimes-Dennis J, Berghella V: Cervical length and prediction of preterm delivery. Curr Opin Obstet Gynecol 2007; 19: 191-195. (Pubitemid 46412109)
19. Berghella V, Owen J, MacPherson C, Yost N, Swain M, Dildy GA 3rd, et al: Natural history of cervical funneling in women at high risk for spontaneous preterm birth. Obstet Gynecol 2007; 109: 863-869. (Pubitemid 46559073)
20. Rebarber A, Ferrara LA, Hanley ML, Istwan NB, Rhea DJ, Stanziano GJ, et al: Increased recurrence of preterm delivery with early cessation of 17α-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007; 196: 224: e1-4.
21. Lang CT, Iams JD: Goals and strategies for prevention of preterm birth: an obstetric perspective. Pediatr Clin North Am 2009; 56: 537-563.